ResMed (NYSE: RMD) announced that SERVE-HF, a multinational, multicenter, randomized controlled Phase III trial did not meet its primary endpoint ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE